CD34 Donor Cell Boost to Treat Poor Graft Function or Graft Failure After Allogeneic Stem Cell Transplant

What this Trial Is About

This research aims to evaluate the use of a CD34 selected stem cell boost for adults who have experienced poor graft function or graft failure after an allogeneic hematopoietic stem cell transplant HSCT. The study focuses on estimating the frequency of successful blood count recovery, including neutrophil and platelet engraftment, and monitoring for graft-versus-host disease GvHD and other side effects related to the CD34 selected cellular product. Participants will receive a single infusion of CD34 selected hematopoietic stem cells obtained from their original donor using the CliniMACS CD34 Reagent System. No extra GvHD prevention treatments will be given, though patients who develop GvHD will be managed according to standard care. Supportive care will be provided based on institutional standards and the treating physicians discretion. During the study, participants will undergo evaluations before the infusion and be monitored for blood count recovery, specifically neutrophil and platelet levels, at day 100 post-procedure. Researchers will also observe for acute and chronic GvHD occurrences up to one year. The trial includes safety monitoring and supportive care throughout. The entire participation period spans at least one year with follow-up assessments to measure outcomes and side effects.

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure